Green Thumb Industries Rallies On News Of Possible Cannabis Rescheduling
Summarize this article with:
Alan Sumler1.39K FollowersFollow5ShareSaveCommentsSummaryNews of possible cannabis rescheduling from the Trump administration caused a rally for US MSOs and Canadian cannabis LPs.Green Thumb Industries' stock price rose more than 50% on the news.The company recently reported in-line Q3-2025 financial results.The stock price is up 24% over the last year and still has room to go higher.I change my rating to a Buy for the company. carlofranco/iStock via Getty Images Green Thumb Industries rallied last week on renewed hope of cannabis rescheduling from the Trump administration. The news appeared in a Washington Post article released on Thursday. US MSOs and Canadian cannabis LPs saw largeThis article was written byAlan Sumler1.39K FollowersFollowWelcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cannabis industry.Analyst’s Disclosure:I/we have a beneficial long position in the shares of GTBIF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.